Article Text

Download PDFPDF
Red cell transfusion thresholds for preterm infants: finally some answers
  1. Edward F Bell
  1. Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA
  1. Correspondence to Dr Edward F Bell, Pediatrics, The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa 52240, USA; edward-bell{at}uiowa.edu

Abstract

Extremely low birthweight infants become anaemic during their care in the neonatal intensive care unit because of the physiological anaemia experienced by all newborn infants compounded by early umbilical cord clamping, blood loss by phlebotomy for laboratory monitoring and delayed erythropoiesis. The majority of these infants receive transfusions of packed red blood cells, usually based on haemoglobin values below a certain threshold. The haemoglobin or haematocrit thresholds used to guide transfusion practices vary with infant status and among institutions and practitioners. Previous smaller studies have not given clear guidance with respect to the haemoglobin thresholds that should trigger transfusions or even if this is the best way to decide when to transfuse an infant. Two large clinical trials of similar design comparing higher and lower haemoglobin thresholds for transfusing extremely low birthweight infants were recently published, the ETTNO and TOP trials. These trials found reassuringly conclusive and concordant results. Within the range of haemoglobin transfusion thresholds studied, there was no difference in the primary outcome (which was the same in both studies), neurodevelopmental impairment at 2 years’ corrected age or death before assessment, in either study. In addition, there was no difference in either study in either of the components of the primary outcome. In conclusion, haemoglobin transfusion thresholds within the ranges used in these trials, 11–13 g/dL for young critically ill or ventilated infants and 7–10 g/dL for stable infants not requiring significant respiratory support, can be safely used without expecting adverse consequences on survival or neurodevelopment.

  • neonatology
  • therapeutics

Data availability statement

No data are available.

Statistics from Altmetric.com

Data availability statement

No data are available.

View Full Text

Footnotes

  • Funding EFB received funding from the NICHD (UG1 HD053109) and the NHLBI (U01 HL112776) for his participation in the TOP trial.

  • Competing interests EFB was the co-principal investigator of the TOP trial.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.